7-methylxanthine is being reformulated into a sustained-release oral therapy aimed at improving long-term control of axial elongation in childhood myopia.
Disruptions to key Middle East logistics corridors are rippling through pharmaceutical supply chains, raising costs and testing resilience, but not yet triggering shortages.
Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.